Medcap Ab · OMXSTO:MCAP

Medcap Ab — Q2 2021 Earnings Presentation

15 slides from Medcap Ab's earnings presentation, July 2021

  1. Slide 1: MedCap Investor in Life Science, July 2021

    a>, ae i MEDCAP INVESTOR IN LIFE SCIENCE July 2021

  2. Slide 2: We create value and contribute to improved quality of life in Life Science

    We create value and contribute to improved quality of life in Life Science 2

  3. Slide 3: MedCap | An active investor in Life Science companies

    MedCap | An active investor in Life Science companies MedTech Segment Specialty Pharma Segment Sales by Segment (MSEK) Geographies Employees 3% 353 22% Sweden 37% Nordic 858 54% Europe 63% Listed on Stockholm 21% RoW Nasdaq Mid Cap MedTech Specialty Pharma 3

  4. Slide 4: Highlights Q2

    Highlights Q2 Q2 2021 • Continued growth in MedTech segment Net Sales (MSEK) 233.4 +12% • Abilia is back on track • Lower Sales in Specialty Pharma, partially EBITDA due to one-time effects in comparison quarter (MSEK) 46.1 +12% • Strong margin in MedTech segment • Positive product mix and raised de

  5. Slide 5: Sales and EBITDA by quarter

    Sales and EBITDA by quarter +12% Net sales per quarter (MSEK) Q2 YTD R12 250 227 223 233 211 206 209 Net Sales 200 200 183 173 188 186 +12% +10% +9% 166 160 175 growth 152 150 139 120 EBITDA +12% +19% +16% 100 growth 50 EBITDA- 20% 19% 20% margin 0 Q1 Q2 Q3 Q1 * Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q

  6. Slide 6: Sales and EBITDA rolling 12 months by quarter

    Sales and EBITDA rolling 12 months by quarter MSEK (Net sales) MSEK (EBITDA) / % 1 000 200 Sales CAGR: 13% 900 EBITDA CAGR: 32% 858 180 834 801 817 786 171 800 757 763 166 160 726 739 734 699 709 155 157 700 672 140 639 147 140 141 596 600 564 127 127 120 525 540 504 508 513 113 500 466 100 439 410

  7. Slide 7: MedTech Q2

    MedTech Q2 Q2 2021 YTD • Healthy growth and strong margin supported by mix Net Sales (MSEK) 153.8 +35% 301.4 +25% • Abilia growth almost 40% • Inpac growth primarily driven by Nutrition EBITDA (MSEK) 42.5 +54% 83.5 +43% • Cardiolex revenue on par with last year, which was boosted by covid • Multi-Pl

  8. Slide 8: MedTech | Sales and EBITDA rolling 12 months by quarter

    MedTech | Sales and EBITDA rolling 12 months by quarter Net Sales and EBITDA-margin – Rolling 12 months MSEK 600 30%  R12 Net sales +21%, primarily 544 driven by the acquisition of Multi-Ply 504 and strong growth in Inpac and 500 483 25% Cardiolex 451 456 444 419 424 431  R12 EBITDA +38% 410 400 4

  9. Slide 9: Specialty Pharma Q2

    Specialty Pharma Q2 Q2 2021 YTD • Sales declined in comparison to last year, which included one-time and covid demand Net Sales (MSEK) 79.7 -17% 154.7 -11% • Specialty pharmaceutical portfolio, represent 48% of segment, growth when adjusting for inventory sale in 2020 EBITDA 11.3 -35% 19.6 -13% (MSE

  10. Slide 10: Specialty Pharma | Sales and EBITDA rolling 12 months by quarter

    Specialty Pharma | Sales and EBITDA rolling 12 months by quarter Net Sales and EBITDA-margin – Rolling 12 months MSEK 400 16%  R12 Net sales -6% 346  R12 EBITDA +6% 350 335 335 14% 327 331 331 318 316 321 320 308 309 310 302 300 284 12% 280 270 265 269 258 256 250 10% 200 8% 150 6% 100 4% 50 2% 0

  11. Slide 11: Sales development for portfolio of Specialty Pharma products

    Sales development for portfolio of Specialty Pharma products Portfolio of attractive products Sales development for selection of key products R12 MSEK 100,0 Attractive platform of own & partner products, pipeline with new product launches, 90,0 established expertise in product development 80,0 +1% (

  12. Slide 12: Sales and EBITDA over time

    Sales and EBITDA over time Net sales (MSEK) EBITDA (MSEK) / % 900 Sales CAGR: 13% 858 200 EBITDA CAGR: 30% 817 834 800 180 757 709 171 160 700 166 157 596 140 600 149 525 120 500 466 406 423 100 400 349 337 80 316 300 78 259 60 187 59 200 40 47 45 41 43 38 100 33 27 20 22 0 7 0 08/09 09/10 10/11 11/

  13. Slide 13: Financial Targets

    Financial Targets Net sales in 3 years Annual EBITDA growth Net debt / EBITDA 1,500 MSEK >15% <3x 13

  14. Slide 14: Investment strategy

    Investment strategy Small and mid-sized Majority Private life science companies Ownership Central / Northern Europe Unlimited Located companies with Ownership period international potential Relationship Targeting Based investments 5 – 10 core investments 14

  15. Slide 15: Thank You!

    Thank You ! Anders Dahlberg Kristina Ekblad CEO CFO anders.dahlberg@medcap.se kristina.ekblad@medcap.se +46 704 269 262 +46 703 322 167 15

MedCap — Q2 2021 Earnings Presentation on 6ix